Exact Sciences (EXAS) Competitors $50.73 +0.57 (+1.14%) (As of 11/13/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends EXAS vs. PRAH, CRL, MEDP, SYNH, ALNY, BIIB, UTHR, INCY, NBIX, and BMRNShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include PRA Health Sciences (PRAH), Charles River Laboratories International (CRL), Medpace (MEDP), Syneos Health (SYNH), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "medical" sector. Exact Sciences vs. PRA Health Sciences Charles River Laboratories International Medpace Syneos Health Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Neurocrine Biosciences BioMarin Pharmaceutical Exact Sciences (NASDAQ:EXAS) and PRA Health Sciences (NASDAQ:PRAH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and community ranking. Do analysts prefer EXAS or PRAH? Exact Sciences presently has a consensus target price of $74.47, indicating a potential upside of 46.80%. Given Exact Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Exact Sciences is more favorable than PRA Health Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exact Sciences 0 Sell rating(s) 1 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.95PRA Health Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer EXAS or PRAH? Exact Sciences received 608 more outperform votes than PRA Health Sciences when rated by MarketBeat users. Likewise, 72.92% of users gave Exact Sciences an outperform vote while only 54.69% of users gave PRA Health Sciences an outperform vote. CompanyUnderperformOutperformExact SciencesOutperform Votes97572.92% Underperform Votes36227.08% PRA Health SciencesOutperform Votes36754.69% Underperform Votes30445.31% Does the media favor EXAS or PRAH? In the previous week, Exact Sciences had 29 more articles in the media than PRA Health Sciences. MarketBeat recorded 29 mentions for Exact Sciences and 0 mentions for PRA Health Sciences. PRA Health Sciences' average media sentiment score of 0.00 beat Exact Sciences' score of -0.05 indicating that PRA Health Sciences is being referred to more favorably in the news media. Company Overall Sentiment Exact Sciences Neutral PRA Health Sciences Neutral Do institutionals and insiders believe in EXAS or PRAH? 88.8% of Exact Sciences shares are owned by institutional investors. Comparatively, 93.9% of PRA Health Sciences shares are owned by institutional investors. 1.4% of Exact Sciences shares are owned by insiders. Comparatively, 1.3% of PRA Health Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable valuation and earnings, EXAS or PRAH? PRA Health Sciences has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than PRA Health Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExact Sciences$2.50B3.76-$204.15M-$1.17-43.36PRA Health Sciences$3.18B3.36$197.04M$3.9042.36 Which has more volatility and risk, EXAS or PRAH? Exact Sciences has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, PRA Health Sciences has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Is EXAS or PRAH more profitable? PRA Health Sciences has a net margin of 6.40% compared to Exact Sciences' net margin of -7.95%. PRA Health Sciences' return on equity of 20.49% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Exact Sciences-7.95% -6.17% -2.98% PRA Health Sciences 6.40%20.49%7.07% SummaryPRA Health Sciences beats Exact Sciences on 10 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.39B$2.94B$5.16B$8.94BDividend YieldN/A1.67%5.04%4.03%P/E Ratio-43.3613.3797.1815.21Price / Sales3.76196.121,298.2292.29Price / Cash2,945.27381.6139.4036.42Price / Book2.923.336.425.98Net Income-$204.15M-$32.88M$115.02M$225.08M7 Day Performance-7.29%-0.65%-0.77%0.37%1 Month Performance-28.51%-1.00%4.85%5.73%1 Year Performance-14.41%38.15%41.37%31.75% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.7731 of 5 stars$50.73+1.1%$74.47+46.8%-14.4%$9.39B$2.50B-43.366,600Analyst ForecastInsider BuyingShort Interest ↓High Trading VolumePRAHPRA Health SciencesN/A$165.21flatN/A+0.0%$10.70B$3.18B50.5218,100Analyst ForecastCRLCharles River Laboratories International4.5527 of 5 stars$215.39+2.4%N/A+21.5%$11.06B$4.13B26.9621,800Earnings ReportAnalyst ForecastInsider SellingShort Interest ↓Analyst RevisionMEDPMedpace4.4449 of 5 stars$362.79+2.7%N/A+31.2%$11.28B$2.07B31.775,900SYNHSyneos HealthN/A$42.98+0.0%N/A+0.0%$4.46B$5.39B62.2928,768Analyst ForecastHigh Trading VolumeALNYAlnylam Pharmaceuticals4.6477 of 5 stars$277.43+1.9%N/A+60.4%$35.21B$1.83B-105.892,100Analyst DowngradeShort Interest ↓BIIBBiogen4.8617 of 5 stars$173.04-0.5%N/A-25.5%$25.22B$9.61B15.637,570Analyst RevisionUTHRUnited Therapeutics4.5399 of 5 stars$410.00+1.8%N/A+77.7%$18.30B$2.76B18.011,168Insider SellingPositive NewsINCYIncyte4.2047 of 5 stars$83.38+1.3%N/A+51.5%$16.06B$3.70B595.612,524Positive NewsNBIXNeurocrine Biosciences4.9797 of 5 stars$125.74+1.4%N/A+13.8%$12.73B$1.89B33.711,400Analyst ForecastBMRNBioMarin Pharmaceutical4.9837 of 5 stars$67.07+0.2%N/A-20.1%$12.61B$2.42B40.163,401 Related Companies and Tools Related Companies PRA Health Sciences Alternatives Charles River Laboratories International Alternatives Medpace Alternatives Syneos Health Alternatives Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EXAS) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersWhat are you hiding Elon?? (Tesla’s secret 69% dividend)Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
